ORIGINAL ARTICLE

Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study

R. Cardona\textsuperscript{a,b}, E. Lopez\textsuperscript{a}, J. Beltrán\textsuperscript{a}, J. Sánchez\textsuperscript{a,b,c,d,}\textsuperscript{*}

\textsuperscript{a} Group of Clinical and Experimental Allergy (GACE) University of Antioquia, Medellin, Colombia
\textsuperscript{b} Clinical Allergology Service University of Antioquia, Medellin, Colombia
\textsuperscript{c} Foundation for the Development of Medical and Biological Sciences (FUNDEMEB), Cartagena, Colombia
\textsuperscript{d} Institute for Immunological Research (III) University of Cartagena, Cartagena, Colombia

Received 24 May 2012; accepted 16 July 2012
Available online 20 December 2012

KEYWORDS
Allergen;
Asthma;
Atopic dermatitis;
Eczema;
Hyposensitization;
Immunotherapy;
Mites;
Rhinitis;
Safety;
Vaccine

Abstract

\textit{Background}: Allergen-specific immunotherapy is a proven, highly effective treatment for IgE-mediated diseases. However, ultra-rush immunotherapy is prescribed infrequently because of the perception that accelerated immunotherapy buildup leads to a higher rate of systemic reactions.

\textit{Objective}: To evaluate the frequency of adverse reactions in patients with IgE-mediated diseases receiving house dust mite (HDM) ultra-rush immunotherapy.

\textit{Methods}: A retrospective, observational study was conducted for patients with IgE-mediated diseases receiving allergen-specific immunotherapy. Subcutaneous immunotherapy with depigmented polymerized mites extract was administered in two refracted doses of 0.2 and 0.3 ml at first injection, and in single 0.5 ml doses in subsequent monthly injections. A 30 min observation time was required after each injection. Systemic reactions were graded using the World Allergy Organisation grading system.

\textit{Results}: 575 patients were included. The age range was 1–83 years. Most patients had respiratory diseases (544) and 101 patients had atopic dermatitis. A total of 27 patients (4.6%) experienced 139 reactions (reactions/injections: 1.9%); 22 patients (3.8%) experienced 134 local reactions (local reactions/injections: 1.8%). Eight patients (1.3%) experienced eight systemic reactions (systemic reactions/injections: 0.1%). Five systemic reactions were grade 2 and three grade 1. Two systemic reactions were reported during buildup. There were no fatalities.

\textit{Conclusion}: Taking into account the possible bias for the retrospective design of this study we observed that immunotherapy for patients with IgE-mediated diseases using a depigmented polymerized mites extract, with an ultra-rush buildup, has similar frequency of systemic reactions than that seen in slower buildup immunotherapy in other studies. Accelerated buildup could improve patients’ adherence and reduce dropout rates.

© 2012 SEICAP. Published by Elsevier España, S.L. All rights reserved.

\textsuperscript{*} Corresponding author.
\textit{E-mail address: jotamsc@yahoo.com (J. Sánchez).}
Introduction

One of the principal factors cited against the widespread adoption of subcutaneous immunotherapy (SCIT) for asthma and other allergic diseases is the risk of serious adverse reactions. In the 1980s a review study reported incidence of systemic reactions in patients receiving SIT for asthma over 30% but in the last 20 years the prevalence of systemic reactions has been reported from 0.25% to 4%. When differential risks exist between therapies, the more risky therapy can only be justified if that therapy offers substantial additional benefit over the safer therapy. Allergen immunotherapy is the only treatment that controls clinical symptoms and simultaneously modifies the course of allergic diseases like asthma, rhinitis, conjunctivitis and atopic dermatitis.

The World Allergy Organisation (WAO) has been making an effort to unify the definition and classification of systemic reactions using five steps according to the system affected and the severity of the reaction; this could be useful for a homogeneous classification between studies and to evaluate possible risk factors such as the type of extract, immunotherapy schedule, and atopic disease.

Slow buildups with several injections per week for two or three months are frequently used to avoid systemic reactions and some articles support a reduction of incidence with slow buildups compared with accelerated buildups when aqueous extracts are used. However, slow buildups have a higher drop-out rate and there are no studies evaluating if slow buildups are better than accelerated buildups when depigmented and polymerized extract are used. Here we present the results of a retrospective study with 575 patients evaluating the safety of IT with a depigmented and polymerized mites extract with a buildup phase of two injections in one day.

Methodology

This retrospective study was designed to evaluate local and systemic reactions after immunotherapy with house dust mites (HDM) during the buildup and/or maintenance dosing. The study was conducted in a single allergy centre with six allergists associated at the University of Antioquia and was approved by the University Institutional Review Board.

Patients receiving SCIT for the period of May 2007–September 2011, were included. Subcutaneous Immunotherapy with depigmented polymerized mites extract (Leti, Madrid Spain) was administered monthly. Mite allergen extracts were administered in two refracted doses of 0.2 and 0.3 ml during buildup, and in single 0.5 ml doses (50 DPP) in subsequent monthly injections (Table 1). A 30 min observation time was required after each injection, for observing and counteracting possible side effects.

Table 1 Ultra rush immunotherapy protocol.

<table>
<thead>
<tr>
<th>Face</th>
<th>Day</th>
<th># Injection</th>
<th>Volume</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buildup</td>
<td>1 day</td>
<td>1</td>
<td>0.2 ml</td>
<td>50 DPP</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.3 ml</td>
<td>50 DPP</td>
</tr>
<tr>
<td>Maintenance</td>
<td>Monthly</td>
<td>1</td>
<td>0.5 ml</td>
<td>50 DPP</td>
</tr>
</tbody>
</table>

Patients or patients’ parents were instructed to identify and report any delayed reaction.

In our population we usually do immunotherapy against a single source of allergens, principally dust mite. In polysensitized patients with two or more sources that prove to be clinically relevant, we vaccinated with those extracts separately, however this is very infrequently and only nine patients of this group needed it.

To classify systemic reactions, the World Allergy Organisation subcutaneous immunotherapy grading system was used. The reactions of patients and the treatment provided were recorded at the time of the reaction taking into account the type of reaction (local, systemic), symptoms, time, organ systems affected.

The clinical history of patients was reviewed for pertinent historical information. Particular attention was focused on sensitisation pattern (monosensitized, polysensitized) and allergic diseases.

Results

Patient characteristics

Five hundred and seventy-five patients received ultra-rush mite immunotherapy. Patients with HDM immunotherapy had a mean age of 15 years with a mode of 10 and ranged from 1 to 83 years of age. Two hundred and ninety-four (51%) patients were female; all patients had an IgE-mediated disease diagnostic by an allergist (Table 2). Five hundred and forty-four (94.6%) patients had a respiratory disease; allergic asthma (313 = 54.4%) or rhinitis (505 = 87.8%). Two hundred and fifty-one (43.6%) had allergic conjunctivitis and 101 (17.5%) atopic dermatitis.

Three patients with HDM immunotherapy received dog dander immunotherapy too. Among the patients receiving mites, 541 were vaccinated with a combination of Der f/Der p; 13 with Blo t/Der f/Der p; 4 with only Der f; 10 with only Der p, and 7 with only Blo t.

Table 2 Demographic features.

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total patients</td>
<td>575 (100%)</td>
</tr>
<tr>
<td>Females</td>
<td>294 (51%)</td>
</tr>
<tr>
<td>Age</td>
<td>15 (1–83)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>313 (54.4%)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>505 (87.8%)</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>251 (43.6%)</td>
</tr>
<tr>
<td>Atopic Dermatitis</td>
<td>101 (17.5%)</td>
</tr>
<tr>
<td>Premedication before immunotherapy</td>
<td>478 (82.6%)</td>
</tr>
</tbody>
</table>
Reactions

Seven thousand two hundred and fifty-six injections with HDM extract were registered; 725 buildup and 6533 maintenance injections. One hundred and twenty-three patients had two or more buildup because immunotherapy was suspended for more than three months. Twenty-seven (4.6%) of 575 patients who received HDM ultra rush immunotherapy experienced a local or systemic reaction, with a total of 139 reactions (reactions/injections: 1.9%).

Local reactions (LR)

Twenty-two patients (3.8%) experienced 134 local reactions (local reactions/injections: 1.8%); 133 were hives and/or erythema and one had pain for three days. Most local reactions were during the first eight months of immunotherapy and in most patients these symptoms did not appear again after the eighth dose. However six patients presented local hives even after 50 injections.

Systemic reactions (SR)

Based on the WAO subcutaneous immunotherapy systemic reaction grading system, eight patients (1.3%) with HDM ultra rush immunotherapy had a total of eight systemic reactions (SR/injections: 0.11%) (Table 3); five grade 2 and three grade 1. Two reactions were during buildup (SR/buildup injections: 0.27%).

Systemic reactions were principally airway symptoms (7/8) and cutaneous symptoms (3/8) (Table 4). All reactions were during the first 30 min after the administration of immunotherapy. There were no delayed reactions. All patients with systemic reactions had rhinitis, and six had asthma. None had atopic dermatitis. There were no fatalities.

We did not pretreat with steroids or antihistamines, but 478 (83.1%) were receiving antihistamine daily as part of their pharmacology treatment for IgE-mediated diseases.

Risk factors for systemic reactions

We observed some variables to identify possible risk factors of SR; the age of patients with SR was under 20 years (5–20). Six patients had asthma; three without control, two partially controlled, and one controlled. All patients with SR were polysensitized and were receiving antihistamines as part of the pharmacology treatment. Three patients with SR had local reactions previously.

<table>
<thead>
<tr>
<th>#</th>
<th>Gender</th>
<th>Age</th>
<th>Polysensitized</th>
<th>Asthma</th>
<th>IT Extract</th>
<th># Doses SR</th>
<th>LR</th>
<th>#LR</th>
<th>Grade SR</th>
<th>Symptoms or signs</th>
<th>Total Epinephrine given</th>
</tr>
</thead>
<tbody>
<tr>
<td>43</td>
<td>F</td>
<td>5</td>
<td>Yes</td>
<td>No</td>
<td>Der f/Der p</td>
<td>2</td>
<td>No</td>
<td>0</td>
<td>2</td>
<td>Hives and wheezing</td>
<td>No</td>
</tr>
<tr>
<td>74</td>
<td>F</td>
<td>20</td>
<td>Yes</td>
<td>Only exercise</td>
<td>Der f/Der p</td>
<td>1*</td>
<td>No</td>
<td>0</td>
<td>2</td>
<td>Hives and wheezing</td>
<td>0,3 mg</td>
</tr>
<tr>
<td>304</td>
<td>F</td>
<td>16</td>
<td>Yes</td>
<td>Partial controlled</td>
<td>Der f/Der p</td>
<td>8</td>
<td>Yes</td>
<td>2</td>
<td>1</td>
<td>Rhinorrea and ocular itching</td>
<td>No</td>
</tr>
<tr>
<td>306</td>
<td>M</td>
<td>5</td>
<td>Yes</td>
<td>No</td>
<td>Der f/Der p</td>
<td>10</td>
<td>No</td>
<td>0</td>
<td>2</td>
<td>Wheezing</td>
<td>No</td>
</tr>
<tr>
<td>312</td>
<td>M</td>
<td>19</td>
<td>Yes</td>
<td>No</td>
<td>Der f/Der p</td>
<td>6</td>
<td>No</td>
<td>0</td>
<td>2</td>
<td>Wheezing and ocular itching</td>
<td>No</td>
</tr>
<tr>
<td>323</td>
<td>F</td>
<td>20</td>
<td>Yes</td>
<td>Partial controlled</td>
<td>Der f/Der p</td>
<td>9</td>
<td>Yes</td>
<td>3</td>
<td>2</td>
<td>Hives, upper airway pruritus and wheezing</td>
<td>No</td>
</tr>
<tr>
<td>413</td>
<td>M</td>
<td>6</td>
<td>Yes</td>
<td>Controlled</td>
<td>Der f</td>
<td>1*</td>
<td>No</td>
<td>0</td>
<td>1</td>
<td>Rhinorrea and ocular itching</td>
<td>No</td>
</tr>
<tr>
<td>534</td>
<td>M</td>
<td>13</td>
<td>Yes</td>
<td>No</td>
<td>Der f/Der p</td>
<td>12</td>
<td>No</td>
<td>0</td>
<td>1</td>
<td>Severe headache</td>
<td>No</td>
</tr>
</tbody>
</table>

### Table 3 Systemic reactions.

### Table 4 Reported symptoms during systemic reactions.

<table>
<thead>
<tr>
<th>Systemic reactions</th>
<th># of Reactions</th>
<th>% of total patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>WAO grade</td>
<td>8</td>
<td>1.3</td>
</tr>
<tr>
<td>Grade 1</td>
<td>3</td>
<td>0.5</td>
</tr>
<tr>
<td>Grade 2</td>
<td>5</td>
<td>0.8</td>
</tr>
<tr>
<td>Grade 3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Grade 4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Grade 5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Eyes</td>
<td>3</td>
<td>0.5</td>
</tr>
<tr>
<td>Skin</td>
<td>3</td>
<td>0.5</td>
</tr>
<tr>
<td>Upper Airway</td>
<td>3</td>
<td>0.5</td>
</tr>
<tr>
<td>Lower Airway</td>
<td>5</td>
<td>0.8</td>
</tr>
<tr>
<td>SNC</td>
<td>1</td>
<td>0.1</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Reactions involving a single organ</td>
<td>2</td>
<td>0.3</td>
</tr>
<tr>
<td>Reactions involving two or more organ systems</td>
<td>6</td>
<td>1</td>
</tr>
</tbody>
</table>
SR treatment
Only one patient with grade 2 SR received adrenaline. Oral antihistamines were given in each patient with SR. Two patients received intramuscular antihistamines. Two patients received intramuscular glucocorticoids and in three inhaled beta agonist was used.

Immunotherapy with other extracts
During the study period only nine patients required immunotherapy with extracts different than HDM. Five patients received dog dander immunotherapy, one with cat at the same time. One patient received ants extract, two hymenopterans and one mosquito.

Discussion

Controlled studies of immunotherapy usually conducted with single allergens, have demonstrated a reduction in respiratory symptoms caused by exposure to grass, cat, house-dust mite, ragweed, Cladosporium, and Alternaria. A meta-analysis of 88 randomised, placebo-controlled studies has confirmed the effectiveness of immunotherapy in asthma and rhinitis, with a significant reduction in asthma symptoms and medication and with improvement in bronchial hyper-reactivity. This meta-analysis included 42 trials for allergy to HDM, 27 for pollen allergy, and 10 for animal dander. On the other hand, only six trials with multiple allergen therapy which is commonly used in United States were included. Most of our patients received the mixed Der f and Der p for immunotherapy; both are mites from the same genus and have high cross-reactivity, however, each one has particular allergens that are not shared between species. Despite its proven benefits, only a small percentage of patients with allergic disease use immunotherapy, in part because of the inconveniences associated with treatment like risk of adverse reactions and because conventional buildup involves once or twice-weekly injections over the course of several months to reach the maintenance dose, requiring frequent visits to a physician’s office and possibly time missed from school or work, which is the principal reason why many patients discontinue treatment before completing the recommended protocol. Accelerated protocols of immunotherapy typically involve a faster buildup, reaching the maintenance dose in a few days or within a month, however these are prescribed infrequently because some studies have reported a higher incidence of reactions, nevertheless others have found no significant difference.

Recently Christopher et al., in a multicentre study with 441 patients, reported that 10.9% of patients receiving cluster immunotherapy experienced a systemic reaction during buildup. As an explanation, they propose that the higher incidence of SR in the study is because it includes only patients with an aggressive buildup protocol consisting of eight visits (two per week) with increasing concentration of mites immunotherapy extract. In our study we did 725 ultra-rush mite buildup in 575 patients and only two presented a systemic reaction during this phase and six present SR during the maintenance phase; a very low frequency in comparison with other studies with accelerated protocols. In our protocol during the buildup we applied the maintenance concentration divided into two injections and patients had to wait for one hour. In the maintenance phase patients only have to wait only for 30 min monthly. This protocol is more comfortable for patients and reduces the frequency of drop-out of immunotherapy or irregular assistance. Different factors could explain the low frequency of adverse reactions in our study compared with the report of Christopher and other articles; We used a depigoid hypoallergenic extract and we generally apply no more than one source of allergens, however it is necessary to be careful when comparing retrospective studies for possible bias. In articles with a retrospective design, some reactions could not be reported under the new classification of the WAO and it is difficult to compare different schedules. However, in our study all patients were clinically evaluated during immunotherapy and any changes in the patient were recorded so it is unlikely to have missed any reaction.

Several previous studies have been published demonstrating the safety of immunotherapy with modified extracts. Casanova et al. included in a prospective observational study 1068 patients with rhinoconjunctivitis and/or asthma sensitized to mites and/or pollen using the same schedule as us and they found five immediate systemic reactions and three delayed grade 2 reactions after 2136 injections (0.66% per patient and 0.4% per injection). The frequency of reactions per injections was slightly higher than found by us, however only one of the eight reactions was with mites; the other seven were with pollen extracts. Hernandez et al., evaluated the safety of immunotherapy after three years of therapy (1837 doses) in a group of 77 patients between two and five years and found only one systemic reaction (0.1%) using a cluster schedule (three days). Similar to the findings of Hernandez et al., in our group of children under five years (74 children) only two had a systemic reaction after doses of 859 (0.2%).

We explored potential risk or protective factors for SR described in other articles, which include gender, age, polysensitization, local reactions and premedication; these factors do not appear to be predictive of subsequent systemic reactions. However, the low incidence of SR in our study makes it difficult to determine a significant difference. We observed that all patients with SR were polysensitized and five had no control or partial control of asthma. So the main reason for SR in our study could be medical mistake.

Some articles report that 20–30% of systemic reactions occurred after one hour of injection, however in our patients all adverse reactions occurred during the first 30 min and we had no delayed reactions. Based on this finding, we considered that the observation period for 30–60 min, as recommended by the American and European consensus of immunotherapy is as good for conventional buildup as for ultra-rush immunotherapy. It has been described that the principal reason for discontinued immunotherapy is large local reactions (18%), schedule conflicts (17%) or systemic reactions (24%). In our population none suspend immunotherapy for local or systemic reactions; the principal reason for stopping immunotherapy was problems with the social security system.

We have preliminary results that show a good clinical response with this ultra-rush immunotherapy schedule in patients with respiratory allergic diseases and even in patients with atopic dermatitis. Until recently, it was generally agreed that immunotherapy should not be used in
patients with atopic dermatitis unless they have another respiratory atopic disease, but the third task force of the AAAAI consensus suggest the use of immunotherapy in patients with atopic dermatitis based on some studies of efficacy. However, the safety of immunotherapy in patients with atopic dermatitis has been little studied and some authors claim for precaution especially in patients with atopic dermatitis polysensitized with respiratory compromised. We evaluated HDM ultra rush immunotherapy in 101 patients with atopic dermatitis all of them polysensitized and 55 with asthma for a mean time of nine months per patient (one buildup nine maintenance per patient) and none presented systemic reactions. These results support the safety of immunotherapy in those patients with atopic dermatitis with or without asthma or polysensitisation.

In conclusion, mite immunotherapy for patients with IgE-mediated diseases using a depigmented polymerized mites extract with an ultra-rush buildup, has similar frequency of systemic reactions than that reported in slow buildup immunotherapy. On the other hand, ultra rush buildup could reduce the number of injections and thus improve patients’ adherence to treatment and reduce the drop-out rate.

Ethical disclosures

This study was approved by the University of Antioquia (Medellin Colombia) Institutional Review Board.

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this investigation

Confidentiality of data. The authors declare that they have followed the protocols of their work centre on the publication of patient data and that all patients included in the study have received sufficient information and have given their informed consent in writing to participate in this study.

Right to privacy and informed consent. The authors have obtained the informed consent of the patients and/or subjects mentioned in the article. The author for correspondence is in possession of this document.

Conflict of interest

Authors have no conflict of interest to declare.

References

24. Heijjaoui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy...
LA COMBINACIÓN MÁS CÓMODA PARA LLEGAR A SU DESTINO

Más comodidad para un mejor cumplimiento

**TOL forte** facilita el cumplimiento gracias a su comodidad, ya que es de concentración única y fácil de administrar.
Ficha técnica: Composición: Extractos alergénicos acuosos en solución salina glicerinada al 50% y fenol al 0,4%, estandarizados biológicamente en unidades HEP, o preparados en mg/ml. Preparación individualizada de extractos alergénicos acuosos. Se preparan de acuerdo con la composición determinada en la prescripción médica. Forma farmacéutica: Solución vía sublingual. Indicaciones: Tratamiento hiposensibilizante (inmunoterapia específica) de las enfermedades alérgicas respiratorias mediadas por IgE (hipersensibilidad tipo I o inmediata), en especial, rinítis alérgica, rinoconjuntivitis alérgica y asma bronquial. Forma de administración: El laboratorio puede facilitar las normas generales de tratamiento que deriven de la técnica de preparación. El médico responsable del tratamiento será quien adapte estas normas a cada enfermo y a su curso clínico. Iniciar el tratamiento en un periodo asintomático. La dosis se administrará en una sola toma diaria, preferentemente en ayunas o antes de las comidas. Las gotas se mantendrán bajo la lava durante 2-3 minutos hasta su total absorción. No aumentar las dosis prescritas ni administrar a intervalos menores de los recomendados. Interacción con otros medicamentos: No se han estudiado. Contraindicaciones: Se consideran como contraindicaciones las generales de los tratamientos hiposensibilizantes. Coexistencia de enfermedad renal. Presencia de enfermedad hematólogica. Hepatopatía crónica. Procesos infecciosos agudos. Cardiopatías y u otros procesos patológicos en los que el paciente recibe betabloqueantes o en los que la adrenalina esté contraindicada. Dermatitis atópica severa. Existencia de enfermedad autoinmune. Estados del paciente en que no puede ofrecer cooperación y trastornos psiquiátricos severos. Con respecto al embarazo, puede constituir una contraindicación, por lo que se debe siempre consultar al especialista en cada caso. El tratamiento no debería iniciarse durante el embarazo. Sin embargo, si el tratamiento ya ha sido iniciado antes del embarazo y la paciente presenta buena tolerancia, la inmunoterapia podría continuar si el especialista lo considera conveniente. Interacciones e incompatibilidades: No se han estudiado. Reacciones adversas: En caso de sobredosificación accidental y/o pacientes muy sensibles, pueden presentarse reacciones locales y/o generales. Ante la aparición de cualquier reacción adversa, antes de proseguir el tratamiento, consultar con el médico prescriptor. Reacción leve: Aumento de la sintomatología alérgica: estornudos, lagrimeo, picor de labios, ojos, oídos, garganta, tos, urticaria localizada, diarrea, dolor abdominal, angiodema y aftas orales. Si aparecen estos síntomas, puede ser necesario un ajuste de dosis o del intervalo entre dosis. Reacción general: Aunque la posibilidad de una reacción general (urticaria generalizada, disnea, cefalea, náuseas, angiodema, sudoración, broncoespasmo, hipotensión, bradicardia, shock) es muy remota, es conveniente tener en cuenta el tratamiento que debe seguirse en estos casos: adrenalina, antihistamínicos, broncodilatadores inhaladores, corticoides, etc. Pauta para la correcta administración de la adrenalina: Se suministrará preferentemente adrenalina por vía intramuscular. Adrenalina 1/1000 a una dosis de 0,01ml/kg de peso/15-20 minutos. Una pauta orientativa en caso de ser necesaria una actuación rápida puede ser la siguiente: Niños hasta los 6 años: 0,2ml, niños de 6 a 12 años: 0,4ml, adultos: 0,5-0,8ml. En caso de persistencia de la reacción sistémica, podrán ser repetidas dichas dosis cada 15-20 minutos, hasta un máximo de 3 veces. Si se considera necesario, trasladar al paciente a un Servicio de Urgencia Hospitalario. Es fundamental el seguimiento periódico del enfermo por el médico prescriptor, al cual incumbe realizar las modificaciones en el tratamiento que crea necesarias para el paciente. Interrupción del tratamiento: Ante cualquier interrupción del tratamiento, pudiera ser necesario continuarlo con una dosis inferior a la última administrada. Como recomendación general ante interrupciones de 7 o más días se aconseja volver a reiniciar el tratamiento. Condiciones de conservación: Conservar por debajo de 30 ºC. No congelar ni someter a cambios bruscos de temperatura. Por tratarse de un producto biológico, puede presentar, según los lotes, ligeras variaciones en la coloración que no afectan a la actividad terapéutica del preparado. Caducidad: Observar la fecha de caducidad que figura en la etiqueta. Fecha de revisión del texto: Diciembre 2010.

BIBLIOGRAFÍA